Castle Creek Biosciences

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Castle Creek Biosciences sits in the top decile of US sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count).

11 total trials none currently recruiting 6 completed early-phase tilt top decile by trial count

Castle Creek Biosciences: 11 sponsored US clinical trials, none currently recruiting.

Castle Creek Biosciences sponsors 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 4 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Bilateral Nasolabial Fold Wrinkles, with 1 trials.

Top-decile sponsor footprint

Castle Creek Biosciences ranks in the top decile of sponsors by registered trial count (#1,226 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Indexed trials (enrollment closed)

11 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 3

Evaluation of D-Fi for the Treatment of Wounds Due to DEB

NCT06892639
ACTIVE NOT RECRUITING Phase 3

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

NCT04213261
TERMINATED Phase 1

A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)

NCT03740724
TERMINATED Phase 1

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT02810951
COMPLETED Phase 2

Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for Vocal Fold Scarring and Age-Related Dysphonia

NCT02120781
TERMINATED Phase 2

Pilot Study of Azficel-T for the Treatment of Restrictive Burn Scars

NCT01858753
COMPLETED Phase 2

Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

NCT00642642
COMPLETED Phase 2

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Facial Wrinkles and Creases

NCT00654654
COMPLETED Phase 3

Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles

NCT00655356
COMPLETED Phase 3

Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles

NCT00649428
COMPLETED Phase 2

Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency

NCT00655889

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5
Phase 3 4

Therapeutic Areas

Bilateral Nasolabial Fold Wrinkles 1
Recessive Dystrophic Epidermolysis Bullosa 1
Dystrophic Epidermolysis Bullosa 1

How the Castle Creek Biosciences early-phase archive is shaped

11 indexed studies, none listed as recruiting (0% open); 6 completed (55%).

Phase mix: 4 late (III/IV) vs 7 early (I/II) (early-phase heavy).

Top condition: Bilateral Nasolabial Fold Wrinkles (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Castle Creek Biosciences: archived-pipeline peers nationwide

Peers matched on 11 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Castle Creek Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Castle Creek BiosciencesAderans Research InstituteAegerion PharmaceuticalsAllena PharmaceuticalsAOBiome10xBio22nd Century Group23andMe3-C Institute for Social Development
Castle Creek Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Castle Creek Biosciences sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 11 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Castle Creek Biosciences page

11 registered trials is a research-attention snapshot, not an endorsement of Castle Creek Biosciences or any single study.

  • None of Castle Creek Biosciences's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Bilateral Nasolabial Fold Wrinkles is the condition Castle Creek Biosciences studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Bilateral Nasolabial Fold Wrinkles trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Castle Creek Biosciences pipeline card: 11 registered trials from official public datasets.Report a data error.